Randomized phase II trial of autologous vaccines consisting of adjuvant GM-CSF plus proliferating tumor cells versus GM-CSF plus dendritic cells loaded with proliferating tumor cells in patients with metastatic melanoma (MAC-VAC)

Trial Profile

Randomized phase II trial of autologous vaccines consisting of adjuvant GM-CSF plus proliferating tumor cells versus GM-CSF plus dendritic cells loaded with proliferating tumor cells in patients with metastatic melanoma (MAC-VAC)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Eltrapuldencel-T (Primary) ; Sargramostim
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms MAC-VAC
  • Most Recent Events

    • 07 Jun 2016 5-year follow-up results from NCT00948480 and NCT00436930 trials (n=72) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2016 5 year follow-up results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top